- Home
- AACG vs BOLD Comparison
AACG vs BOLD Comparison
Compare AACG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- BOLD
- Stock Information
- Founded
- AACG 1999
- BOLD 2018
- Country
- AACG China
- BOLD United States
- Employees
- AACG N/A
- BOLD N/A
- Industry
- AACG Other Consumer Services
- BOLD
- Sector
- AACG Real Estate
- BOLD
- Exchange
- AACG Nasdaq
- BOLD Nasdaq
- Market Cap
- AACG 24.4M
- BOLD 24.4M
- IPO Year
- AACG N/A
- BOLD 2024
- Fundamental
- Price
- AACG $1.96
- BOLD $1.16
- Analyst Decision
- AACG
- BOLD Buy
- Analyst Count
- AACG 0
- BOLD 4
- Target Price
- AACG N/A
- BOLD $4.00
- AVG Volume (30 Days)
- AACG 690.5K
- BOLD 81.7K
- Earning Date
- AACG 08-06-2025
- BOLD 08-05-2025
- Dividend Yield
- AACG N/A
- BOLD N/A
- EPS Growth
- AACG N/A
- BOLD N/A
- EPS
- AACG N/A
- BOLD N/A
- Revenue
- AACG $39,064,701.00
- BOLD N/A
- Revenue This Year
- AACG N/A
- BOLD N/A
- Revenue Next Year
- AACG N/A
- BOLD N/A
- P/E Ratio
- AACG N/A
- BOLD N/A
- Revenue Growth
- AACG 15.19
- BOLD N/A
- 52 Week Low
- AACG $0.50
- BOLD $1.00
- 52 Week High
- AACG $2.30
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- AACG 60.72
- BOLD N/A
- Support Level
- AACG $1.42
- BOLD N/A
- Resistance Level
- AACG $2.13
- BOLD N/A
- Average True Range (ATR)
- AACG 0.38
- BOLD 0.00
- MACD
- AACG 0.04
- BOLD 0.00
- Stochastic Oscillator
- AACG 72.58
- BOLD 0.00
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.